BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors.
BMC Cancer
; 20(1): 129, 2020 Feb 17.
Article
en En
| MEDLINE
| ID: mdl-32066410
ABSTRACT
BACKGROUND:
Colorectal cancer (CRC) is a heterogeneous disease with a complex biology and a wide number of altered genes such as BRAF, KRAS and PIK3CA. Advances with new-targeted therapies have been achieved and available treating options have prolonged patient's survival. However, BRAF-mutated CRC patients remain unresponsive to available therapies with RAF inhibitors (RAFi) alone or combined with ErbB inhibitors (ErbBi). These unmet needs require further exploitation of oncogenic signaling in order to set up individualized treatments.METHODS:
To this end, we tested the efficacy of single agent or combined treatments using the BRAFi, vemurafenib and two different ErbBi panitumumab and afatinib in CRC cells characterized by different molecular phenotypes.RESULTS:
Combination strategies with BRAFi and ErbBi achieved a better response in BRAFV600E mutated cells expressing high levels of ErbB2.CONCLUSIONS:
Our findings support the importance of ErbB2 evaluation in BRAF-mutated CRC patients and its role as a positive predictor factor of response to BRAFi/ErbBi combination.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias Colorrectales
/
Transducción de Señal
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Receptor ErbB-2
/
Proteínas Proto-Oncogénicas B-raf
/
Mutación
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
BMC Cancer
Asunto de la revista:
NEOPLASIAS
Año:
2020
Tipo del documento:
Article
País de afiliación:
Italia